Schrijvers, Dorien

Publishing since 1988 (Dinosaur)

Has published 67 publications in 23 years

Number of publications published per year by Schrijvers, Dorien. (Source : PubMed)

Distribution of publications types for Schrijvers, Dorien. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)

Recent publications

•  Specenier P, Rasschaert M, Van den Brande J, Dyck J, Schrijvers D, Huizing MT, Vermorken JB. Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study.  Anticancer Drugs  2010;21;3  
•  Cherny N, Catane R, Schrijvers D, Kloke M, Strasser F. European Society for Medical Oncology (ESMO) Program for the integration of oncology and Palliative Care: a 5-year review of the Designated Centers' incentive program.  Ann. Oncol.  2010;21;2  
•  Specenier PM, Van Den Brande J, Schrijvers D, Huizing MT, Altintas S, Dyck J, Van Den Weyngaert D, Van Laer C, Vermorken JB. Docetaxel, ifosfamide and cisplatin (DIP) in squamous cell carcinoma of the head and neck.  Anticancer Res.  2009;29;12  
•  Schrijvers D, Maas YJ, Sabbe BG. Effects of fluoxetine on fine motor performance in dysthymia: an 8-week, nonrandomized, open-label study.  Clin Ther  2009;31;1  
•  Vandebroek AJ, Schrijvers D. Nutritional issues in anti-cancer treatment.  Ann. Oncol.  2008;19 Suppl 5  
•  Specenier PM, Van den Weyngaert D, Van Laer C, Weyler J, Van den Brande J, Huizing MT, Dyck J, Schrijvers D, Vermorken JB. Phase II feasibility study of concurrent radiotherapy and gemcitabine in chemonaive patients with squamous cell carcinoma of the head and neck: long-term follow up data.  Ann. Oncol.  2007;18;11  
•  Schrijvers D, Meijnders P. Palliative care in adolescents.  Cancer Treat. Rev.  2007;33;7  
•  Fordel E, Thijs L, Martinet W, Schrijvers D, Moens L, Dewilde S. Anoxia or oxygen and glucose deprivation in SH-SY5Y cells: a step closer to the unraveling of neuroglobin and cytoglobin functions.  Gene  2007;398;1-2  
•  Schrijvers D. Pain control in cancer: recent findings and trends.  Ann. Oncol.  2007;18 Suppl 9  
•  Rasschaert M, Schrijvers D, Van den Brande J, Dyck J, Bosmans J, Merkle K, Vermorken JB. A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours.  Br. J. Cancer  2007;96;11  

[ See timeline ] [ See all publications ]